International variation in invasive care of the elderly with acute coronary syndromes.

AIMS To explore variations in invasive care of the elderly with acute coronary syndromes across international practice. METHODS AND RESULTS Using combined populations from the SYMPHONY and 2nd SYMPHONY trials, we describe 30-day cardiac catheterization in elderly (> or = 75 years; n = 1794) vs. younger patients (< 75 years; n = 14,043) after multivariable adjustment and by region of enrolment. The use of cardiac catheterization and revascularization were not protocol-specified. Elderly patients (median age 78 years) were more often female and more frequently had hypertension, diabetes, prior myocardial infarction, and prior coronary bypass surgery. Overall, they underwent less cardiac catheterization than younger patients [53 vs. 63%; adjusted OR 0.53 (0.46, 0.60)]. The absolute rate of cardiac catheterization in the elderly varied from 77% (vs. 91% in younger patients) in the US cohort to 27% (vs. 41% in younger patients) in the non-US cohort. Revascularization of elderly who underwent cardiac catheterization was also higher in US than non-US cohorts (71.3 vs. 53.6%). There was a significant interaction between the patient age and the use of catheterization across US and non-US regions of enrolment, as well as differences in the predictors of catheterization in the elderly. Despite these findings, after adjustment, 90-day rates of death and death or myocardial infarction (MI) were not significantly different in elderly who underwent catheterization compared with those who did not. CONCLUSION Although older age is universally predictive of lower use of cardiac catheterization, marked variation in catheterization of the elderly exists across international practice. Demonstrated differences in patterns of use suggest a lack of consensus regarding optimal use of an invasive strategy in the elderly.

[1]  R. J. Winter,et al.  Early invasive vs. selectively invasive management for acute coronoary syndromes , 2006 .

[2]  J. Tijssen,et al.  Early invasive versus selectively invasive management for acute coronary syndromes. , 2005, The New England journal of medicine.

[3]  S. Yusuf,et al.  Routine vs selective invasive strategies in patients with acute coronary syndromes: a collaborative meta-analysis of randomized trials. , 2005, JAMA.

[4]  C. Cannon,et al.  The effect of routine, early invasive management on outcome for elderly patients with non-ST-segment elevation acute coronary syndromes , 2004 .

[5]  R. Califf,et al.  International variation in the use of evidence-based medicines for acute coronary syndromes. , 2003, European heart journal.

[6]  M. Mcclellan,et al.  Cardiac Procedure Use and Outcomes in Elderly Patients with Acute Myocardial Infarction in the United States and Quebec, Canada, 1988 to 1994 , 2003, Medical care.

[7]  M. Pfisterer,et al.  Outcome of elderly patients with chronic symptomatic coronary artery disease with an invasive vs optimized medical treatment strategy: one-year results of the randomized TIME trial. , 2003, JAMA.

[8]  F. Roche Predictors of 90-day outcome in patients stabilized after acute coronary syndromes , 2003 .

[9]  P. Poole‐Wilson,et al.  Interventional vs. conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the british heart foundation RITA 3 randomized trial☆ , 2003 .

[10]  F. C. Dougherty,et al.  Predictors of 90-day outcome in patients stabilized after acute coronary syndromes. , 2003, European heart journal.

[11]  G. Specchia,et al.  Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. , 2002, European heart journal.

[12]  J. W. Schaeffer,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non–ST-segment elevation myocardial infarction—summary article , 2002 .

[13]  Carl J Pepine,et al.  ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction--summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients , 2002, Journal of the American College of Cardiology.

[14]  K. Fox,et al.  Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial , 2002, The Lancet.

[15]  C. Vassanelli,et al.  [Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban]. , 2001, Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology.

[16]  K. Alexander,et al.  Representation of elderly persons and women in published randomized trials of acute coronary syndromes. , 2001, JAMA.

[17]  K. Alexander,et al.  Post-myocardial infarction risk stratification in elderly patients. , 2001, American heart journal.

[18]  E. Braunwald,et al.  Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. , 2001, The New England journal of medicine.

[19]  Second Symphony Investigators Randomized Trial of Aspirin, Sibrafiban, or Both for Secondary Prevention After Acute Coronary Syndromes , 2001, Circulation.

[20]  R. Califf,et al.  Temporal evolution in the management of acute ST elevation myocardial infarction: the seven-year GUSTO experience from canada and the united states. The North American GUSTO-I and GUSTO-III investigators. , 2000, The Canadian journal of cardiology.

[21]  R. Califf,et al.  Canadian-American Differences in the Management of Acute Coronary Syndromes in the GUSTO IIb Trial: One-Year Follow-Up of Patients Without ST-Segment Elevation , 2000, Circulation.

[22]  R. Califf,et al.  Comparison of sibrafiban with aspirin for prevention of cardiovascular events after acute coronary syndromes: a randomised trial , 2000, The Lancet.

[23]  F. Ragmin Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999, The Lancet.

[24]  L. Newby,et al.  Long-term oral platelet glycoprotein IIb/IIIa receptor antagonism with sibrafiban after acute coronary syndromes: Study design of the Sibrafiban versus aspirin to Yield Maximum Protection from ischemic Heart events post-acute cOroNary sYndromes (SYMPHONY) trial , 1999 .

[25]  L. Wallentin,et al.  Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study , 1999 .

[26]  E. Braunwald,et al.  Influence of race, sex, and age on management of unstable angina and non-Q-wave myocardial infarction: The TIMI III registry. , 1996 .

[27]  D. Mark,et al.  Differences in the Treatment of Myocardial Infarction Between the United States and Canada: A Survey of Physicians in the GUSTO Trial , 1995, Medical care.

[28]  R. Califf,et al.  Variations in Patient Management and Outcomes for Acute Myocardial Infarction in the United States and Other Countries: Results From the GUSTO Trial , 1995 .

[29]  K. Lee,et al.  Variations in patient management and outcomes for acute myocardial infarction in the United States and other countries. Results from the GUSTO trial. Global Utilization of Streptokinase and Tissue Plasminogen Activator for Occluded Coronary Arteries. , 1995, JAMA.

[30]  K. Lee,et al.  Use of medical resources and quality of life after acute myocardial infarction in Canada and the United States. , 1994, The New England journal of medicine.

[31]  G. Lamas,et al.  A comparison of management patterns after acute myocardial infarction in Canada and the United States. The SAVE investigators. , 1993, The New England journal of medicine.

[32]  H. White,et al.  Comparative case fatality analysis of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial: variation by country beyond predictive profile. The Investigators of the International Tissue Plasminogen Activator/Streptokinase Mortality Trial. , 1993, Journal of the American College of Cardiology.